MENU
JUN 20, 2019 1:30 PM PDT

Introducing the therascreen FGFR RGQ RT-PCR Kit and Day-One Readiness at Insight Molecular Labs

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Chief Operating Officer, Insight Genetics
    Biography
      Dr. Hout is the Chief Operating Officer at the Nashville, TN based diagnostic company, Insight Genetics, Inc.

      Dr. Hout received his Ph.D. in molecular virology and has more than 15 years of assay development and design experience throughout his tenure.

      Dr. Hout has published and presented extensively on the development, validation, and performance of both qPCR and Next Generation sequencing clinical assays in peer reviewed journals and at national meetings.

      He is also board certified as a licensed Laboratory Supervisor and has extensive experience with both CLIA and CAP compliance.
    • Global Product Manager, Oncology & Precision Diagnostics, QIAGEN
      Biography
        Ben is a member of the Oncology Diagnostics Global Product Management team at QIAGEN, with responsibility for commercialisation of innovative new Companion Diagnostic tests around the world, including the therascreen FGFR RGQ RT-PCR Kit recently approved by the FDA in the USA.

        A molecular biologist and immunologist by qualification, he has over a decade of experience in the IVD industry covering a range of roles including assay development, manufacturing and product management.

        He is based in Manchester, UK, the QIAGEN global centre of excellence for companion diagnostic development, where the FGFR RGQ RT-PCR Kit was originally developed.

      Abstract

      The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment with therapeutics that are selectively active against disease cases which harbor these characteristics. This approach is transforming the care that patients receive, particularly in oncology. In this presentation, Dr. Benjamin Chaffey and Dr. David Hout will firstly introduce the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, which was recently co-approved by the FDA as the companion diagnostic test to guide prescription of BALVERSA™, a novel FGFR inhibitor, in cases of urothelial cancer. They will then describe how patient access to testing has been made available as rapidly as possible through Insight Genetics’ participation in the QIAGEN Day-One Readiness program for this test.

      Learning Objectives: 

      1. To gain a more complete understanding of the importance of FGFR testing when identifying treatment options for patients suffering with advanced urothelial cancer
      2. To learn how the Day-One Readiness program enables QIAGEN and partner labs such as Insight to accelerate the availability of innovative new tests to health care providers and thereby improve the quality of care which can be delivered to patients.


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      Loading Comments...
      Show Resources